Comparison of the effectiveness of Acapella and BreatheMAX devices on secretion clearance and quality of life in patients with non-cystic fibrosis Bronchiectasis randomized crossover trial.
Phase 4
- Conditions
- patients with non cystic fibrosis bronchiectasis who have daily sputum productionBronchiectasis, sputum
- Registration Number
- TCTR20230603003
- Lead Sponsor
- Science Promotion Fund Research and Innovation (SCF Fund) : Fundamental Fund Type Fund for the fiscal year 2023
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Age is 18-85 years,
-Confirmed diagnosis of bronchiectasis with or without other respiratory disease (eg, COPD) by physician (X-rays, CT chest)
-reported daily sputum production (>10 ml) or crackles or rhonchi during listening of lung's auscultation and rhonchal fremitus.
-Good cooperation and able to follow the command
-Stable vital signs (temperature, heart rate, blood pressure, respiratory rate)
Exclusion Criteria
- cystic fibrosis
-SpO2 < 90%
-Active pulmonary tuberculosis
-Exacerbation within 1 months
-Any cancer
-Cardiac dysfunction & hemodynamic instability
-History of brain aneurism or retinal detachment, recent facial, oral, or skull surgery, abdominal aneurism
-Neurological: old CVD and SCI
-Pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sputum wet weight before, during and after gram
- Secondary Outcome Measures
Name Time Method Health related quality of life before and after COPD assessment test,Cough transportability measurement before, during and after centimeter